Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ABSTRACT

Background. Favipiravir (FPV) is an orally administrable antiviral drug that selectively inhibits its RNA-dependent RNA polymerase and has been repurposed for COVID-19 treatment. There is limited information on the use of FPV in kidney transplant recipients (KTx), who often have multiple comorbidities and run a higher risk for death from COVID-19.

Methods. We retrospectively reviewed all KTx at our institution who got sick with COVID-19 between March 1, 2020, and May 31, 2021, and who received FPV (loading dose of 1800 mg on day 1, maintenance dose 2 × 800 mg/d for 5-14 days) as part of their COVID treatment. We analyzed demographics, clinical course, laboratory data, management, and outcome.

Results. Nine KTx with COVID-19 received FPV; all were hospitalized. The median age was 52 years (range, 32-60 years), and women were predominant (77.7%). Eight KTx had pulmonary involvement on chest radiograph. On admission 1 patient had mild, 5 had moderate, 2 had severe, and 1 had critical disease. Leukopenia and increased creatinine were universally noted. Three patients had disease progression under treatment. Seven patients (77.7%) required additional oxygen, and 4 (57.1%) needed intensive care unit admission. Three KTx died, resulting in an overall mortality of 33.3%. Survivors did not show increased transaminases or creatinine during or after FPV treatment; leukocytes, neutrophils, and platelets improved on discharge compared with admission values.

Conclusions. FPV appears well tolerated by KTx with COVID-19, but its clinical benefit remains unclear. Larger analyses are needed.

During the first year of the COVID-19 pandemic there was a frustrating and protracted lack of effective antiviral treatments, so that supportive therapy and decreasing immunosuppression remained the cornerstones of COVID-19 management in transplant recipients. Repurposed drugs such as hydroxychloroquine, antiretrovirals, and remdesivir have also been used with negative, conflicting, or inconclusive results [1,2].

Favipiravir (FPV) is a synthetic prodrug approved in Japan for the management of the emerging 2014 influenza pandemic, which has also been repurposed and tested in COVID-19. It inhibits the RNA-dependent RNA polymerase leading to termination of viral protein synthesis [3]. The influenza dosing regimen in Japan is a loading dose of 3200 mg on day 1, followed by a maintenance dose of 600 mg twice daily on days 2 to 5. Apart for its known teratogenic effect, FPV appears to have a good safety profile. However, hyperuricemia, diarrhea, reduced neutrophil count, transaminitis, and QTc prolongation have been reported as potential adverse effects [4]. The limited experience with FPV for COVID treatment suggests that this drug induces viral clearance by 7 days and contributes to clinical improvement within 14 days, especially in patients with mild to moderate illness, and that FPV may be an option for moderate
COVID-19 pneumonia treatment [5–8]. However, the risk of adverse events requires careful consideration.

So far, the literature on the use of FPV in kidney transplant recipients (KTx) with COVID-19 is limited to 1 retrospective series and several case reports, totaling less than 70 patients [9–12]. There is no documented benefits of FVP in this group of patients because of the limited number of studies, most of them being case reports. In addition, the results are difficult to interpret because of simultaneous administration of other medications. Thus, the efficiency and safety of FPV in transplant recipients remain unclear. We herein report our experience with 9 KTx infected with SARS-CoV-2 treated with FPV.

MATERIALS AND METHODS

We retrospectively reviewed all KTx who underwent transplant at the Clinical Institute of Urology and Renal Transplantation in Cluj-Napoca, Romania, who got sick with COVID-19 between March 1, 2020 and May 31, 2021. COVID-19 was defined as a positive result for SARS-CoV-2 RNA on real-time polymerase chain reaction assay of a nasopharyngeal swab and typical COVID-19 symptoms. We identified all the patients who were treated with FPV at any stage of their treatment and retrieved demographic and clinical data including age, sex, comorbidities, duration of symptoms, clinical course, and laboratory data.

FPV (FluGuard, Alliance Health care, Romania) treatment was started on admission. All patients received FPV with a loading dose of 2 × 1800 mg and a maintenance dose of 2 × 800 mg for 5 to 7 days. An experienced transplant nephrologist adjusted the immunosuppression regimen according to the ERA–EDETA Developing Education Science and Care for Renal Transplantation in European States expert opinion [13]. Dexamethasone, tocilizumab, antipyretics, cough suppressants, and antibiotics were given at the discretion of the medical teams attending the patients. All patients received anticoagulant therapy with low-molecular-weight heparin during the hospital stay.

Acute kidney injury was defined as an increase in serum creatinine by ≥ 0.3 mg/dL within 48 hours or an increase to 1.5 times or more from baseline based on the definition of Kidney Disease: Improving Global Outcomes. Disease severity was classified from mild to critical according to the National Institutes of Health guidelines [14]. The comorbidity assessment was performed using the age-adjusted Charlson Comorbidity Index [15]. Baseline kidney graft function (estimated glomerular filtration rate) was assessed on data collected at the last check-up before COVID-19 using the Chronic Kidney Disease Epidemiology Collaboration formula. The study was reviewed and approved by the Institutional Review Board of the Clinical Institute of Urology and Renal Transplantation (1/2021).

### Statistical Analysis

Discrete data were described by their frequency expressed as a percentage. Continuous data were expressed as median and range unless otherwise stated. Given the small group size and data distribution, Wilcoxon signed-rank test was used for data analysis. A P value < .05 was considered significant.

### RESULTS

#### Patients

Nine KTx diagnosed as having COVID-19 during the study period received FPV, all during the second wave of the pandemic (autumn/winter 2020). The patients in this series had a median age of 52 years (range: 32-60 years) and were predominately women (77.7%). All but 1 were deceased donor kidney recipients and had a median time since transplant of 57 months (range: 4-319 months). Eight patients were being administered tacrolimus therapy, mycophenolate mofetil, and prednisolone at the time of COVID-19 diagnosis, whereas 1 was on monotherapy with azathioprine. Basiliximab was used for tolerance induction in 8 cases. The characteristics of all 9 patients are detailed in Table 1.

All KTx but 1 had bilateral opacities typical for COVID-19 noted on initial chest radiography. The pulmonary involvement ranged from 10% to > 75% of the lung parenchyma.

Laboratory data at the time of diagnosis frequently revealed leukopenia with median white blood cell count of 4.16 × 10^3/mL (range, 2.1-10.62 × 10^3/mL), median neutrophil count of 2.74 × 10^9/mL (range, 1.06-9.45 × 10^9/mL), and median lymphocyte count of 195/mL (range, 460-1690/mL). At admission, liver function tests were largely within normal range, with median alanine aminotransferase of 39 IU/L (range, 13-52 IU/L) and aspartate aminotransferase of 57 IU/L (range, 20-143 IU/L). We recorded a wide variation in admission values for ferritin (median, 839 ng/mL; range, 40.5-3920 ng/mL), D-dimers (median, 4.24 mg/L FEU; range, 0.26-1437 mg/L FEU), and lactate dehydrogenase (median, 205 U/L; range, 136-673 U/L).

#### Management and Outcome

All patients were hospitalized. Immunosuppression regimen was modified in all but 1 patient: antimetabolites (mycophenolate

### Table 1. Demographic and Clinical Data of the Patients Included in the Study

| Patient No. | Age | Sex | Time After Transplant, mo | BMI | CCI | eGFR | Symptoms | Length of Symptoms Before Admission, d | Disease Severity at Admission |
|-------------|-----|-----|---------------------------|-----|-----|------|---------|--------------------------------|-----------------------------|
| 1           | 52  | F   | 33                        | 32.8| 4   | 51   | Fever, cough, malaise             | 11                          | Moderate                    |
| 2           | 42  | M   | 21                        | 20.3| 2   | 73   | Fever, diarrhea, cough, anosmia   | 2                           | Moderate                    |
| 3           | 56  | F   | 23                        | 22.1| 3   | 21.8| Fever, SOB, diarrhea, malaise     | 9                           | Moderate, progression to severe |
| 4           | 60  | F   | 61                        | 28.5| 4   | 12   | Fever, cough, SOB, anosmia, diarrhea | 10                          | Severe                      |
| 5           | 58  | M   | 62                        | 24.3| 3   | 64.2| Fever, cough, malaise             | 3                           | Moderate                    |
| 6           | 40  | F   | 4                         | 31.7| 3   | 18.8| Fever, cough, SOB, diarrhea, malaise | 2                           | Critical                     |
| 7           | 39  | F   | 306                       | 28.1| 2   | 44   | Cough, pharyngitis                | 2                           | Mild                        |
| 8           | 52  | F   | 57                        | 28.6| 3   | 68.5| Fever, cough, SOB, malaise        | 3                           | Severe, progression to critical |
| 9           | 32  | F   | 58                        | 27.3| 3   | 73   | Cough, SOB, malaise               | 9                           | Moderate, progression to severe |
mofetil, mycophenolic acid) were stopped in all but 1 patient (#7), and tacrolimus was reduced in all KTx receiving the drug. In 4 patients with severe or critical disease, all receiving high-dose dexamethasone, immunosuppression was completely withdrawn.

Acute kidney injury developed in 2 patients, both developing critical disease and ultimately requiring renal replacement therapy. Seven of 9 patients (77.7%) required additional oxygen and 4 (57.1%) were admitted to the intensive care unit. Three of these patients ultimately died, resulting in an overall mortality of 33%. All the other patients are alive, with a follow-up of at least 6 months. A detailed account on the clinical course of each patient is presented in Table 2.

On discharge, survivors did not show increased transaminases, and creatinine level was lower that at admission in all patients (median, 1.18 mg/dL [range, 0.84-1.3 mg/dL]; \( P = .06 \)). In addition, leukocytes, neutrophils, and platelets have all improved in absolute numbers (\( P = .06 \)).

**DISCUSSION**

Organ transplant recipients are considered a risk group for unfavorable outcome regarding COVID-19, with reported mortality frequently exceeding 20% [1,16,17]. This disproporionately high mortality is most likely because of the lifelong immunosuppression affecting both the cellular and humoral immunity as well as the frequent comorbidities such as diabetes, overweight, cardiovascular diseases, and poor renal function.

Although administered on hospitalization, FPV was given relatively late in the course of the disease, most patients reporting COVID symptoms for longer than 1 week before seeking medical assistance. Joshi et al, in a preliminary report on 2158 COVID-19 cases from a Japanese observational registry where FPV was started within 3 days from diagnosis, reported the favorable outcome regarding COVID-19, with reported mortality at 7 days from the start of FPV therapy as 73.8%, 66.6%, and 40.1% for mild, moderate, and critical disease and ultimately requiring renal replacement therapy. It is unlikely that FPV has contributed to this worsening because an acute kidney failure requiring renal replacement therapy. It is unlikely that FPV has contributed to this worsening because an acute kidney failure requiring renal replacement therapy. It is unlikely that FPV has contributed to this worsening because an acute kidney failure requiring renal replacement therapy.
This case series lacks a control group, making it difficult to establish the efficiency of FPV compared with other treatments. Finding a proper control group matching the age, sex, comorbidities, and, above all, disease severity would have been difficult or impossible. For these reasons, we did not perform direct comparisons with patients receiving other treatments such as remdesivir and standard supportive therapy. Previous analyses in similar, larger patient groups showed an in-hospital mortality during the second COVID wave at around 27% [20,21]. Because the overall mortality in this series was 33.3%, it does not appear that FPV obviously impacted mortality, although this statement is purely speculative in the absence of adequate comparisons with a well-matched control group. The mortality in a group of Turkish KTx with COVID pneumonia similarly treated with FPV was almost identical (35.7%) [9].

The dramatic clinical course of a recipient who has recently undergone transplant, with a duration between symptom start to death of only 9 days, further underscores the negative impact of immunosuppression. It is customary that more intense immunosuppression is applied in the first months after transplant, which together with the persistent effect of the induction therapy on the cellular immunity may explain the rapid progression toward death. Two large Spanish analyses confirmed a significantly higher risk for death in recipients who have recently undergone transplant (within 12 months from transplant) [1,20].

The present study has several other limitations besides the absence of a control group. This was a retrospective observational study reporting on a small number of patients, and selection bias might have occurred. Although two-thirds of patients presented with mild and moderate disease, which is the typical disease severity when FPV is currently used, some patients were sicker or progressed toward more severe forms. The use of FPV in severe and critical cases was probably motivated by the limited availability of remdesivir during the second wave, although it is unlikely that other treatments including remdesivir would have significantly improved the mortality.

Secondly, time to viral clearance and viral load was not assessed uniformly during the hospitalization but only on discharge or around the time of patient death. Whereas this could have been interesting from epidemiologic and academic standpoint, it is known that SARS-CoV-2 can be detected in the respiratory samples of over half of the patients with severe disease up to the fourth week after symptom onset, and even longer time from other sampling locals [22,23].

CONCLUSIONS

This small case series does not allow firm conclusions about the efficiency of FPV on disease progression or mortality but suggests that a brief treatment is well tolerated by KTx. Further studies and larger meta-analyses are mandated to explore a potential clinical benefit of FPV in this vulnerable patient group.

ACKNOWLEDGMENTS

We thank all of our colleagues involved in the care of patients with COVID-19.

REFERENCES

[1] Coll E, Fernández-Ruiz M, Padilla M, Moreso F, Hernández-Vicente A, Yañez I, et al. COVID-19 in solid organ transplant recipients in Spain throughout 2020: catching the wave? Transplantation 2021; 105:2146–55.
[2] Oltean M, Ottean M, Boldor C, Slavcovic A, Cismaru C, Lupșe M, et al. COVID-19 after kidney transplantation: early outcomes and renal function following antiviral treatment. Int J Infect Dis 2021; 104:426–32.
[3] Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smeek DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446–54.
[4] Pilkington V, Peppertell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad 2020;6:45–51.
[5] Manabe T, Kambayashi D, Akatsu H, Kado K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21:489.
[6] Shinkai M, Tsuchima K, Tanaka S, Hagiwara E, Tarumoto N, Nakada I, et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect Dis Ther 2021;10:2489–509.
[7] Karatas E, Aksylo L, Ozaslan E. Association of early favipiravir use with reduced COVID-19 fatality among hospitalized patients. Infect Chemother 2021;53:300–7.
[8] Udwaadia ZF, Singh P, Barkate H, Patil S, Rangswala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis 2021;103:62–71.
[9] Karatas M, Tatar E, Simsek C, Yildirim AM, Ari A, Zengel B, et al. COVID-19 pneumonia in kidney transplant recipients: a promising treatment algorithm in the absence of a disease-specific drug. J Med Virol 2021;93:5789–97.
[10] Yoshinaga K, Araki M, Wada K, Hasegawa K, Sekito T, Miyake S, et al. Successful deceased donor kidney transplantation to a recipient with a history of COVID-19 treatment. J Infect Chemother 2021;27:1097–101.
[11] Koba H, Yoned a T, Kaneda T, Ueda T, Kimura H, Kasahara K. Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: a case series. Clin Case Rep 2020;8:3143–8.
[12] Dirim AB, Demir E, Ucar AR, Garayeva N, Safak S, Oto OA, et al. Fatal SARS-CoV-2 infection in a renal transplant patient? An ERA-EDTA DESCARTES expert opinion. Nephrol Dial Transplant 2020;35:899–904.
[13] Maggiore U, Abramowicz D, Crespo M, Mariat C, Mjoen G, Peruzzi L, et al. How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrol Dial Transplant 2020;35:899–904.
[14] National Institutes of Health COVID-19 Treatment Guidelines Panel. Clinical spectrum of SARS-CoV-2 infection, https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/; 2021 [accessed 21.10.09].
[15] Oltean S, Tatulescu D, Bondor C, Slavcovic A, Cismaru C, Lupșe M, et al. Charlson’s weighted index of comorbidities is useful in assessing the risk of death in septic patients. J Crit Care 2012;27:370–5.
[16] Oltean M, Săftelând JM, Bagge J, Ekelund J, Fellidl M, Schult A, et al. COVID-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic. Infect Dis (Lond) 2020;52:830–7.
[17] Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Alvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int 2020;98:1540–8.
[18] Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021;102:501–8.
[19] Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020;64:e01897-20.

[20] Villanego F, Mazuecos A, Pérez-Flores IM, Moreso F, Andrés A, Jiménez-Martín C, et al. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. Am J Transplant 2021;21:2573–82.

[21] Elec FI, Bolboaca SD, Muntean A, Elec AD, Cismaru C, Lupșe M, et al. Comparing the first and second wave of COVID-19 in kidney transplant recipients: an East-European perspective. Eur Surg Res 2021;298:305.

[22] Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443.

[23] Bora I, Gogoi S, Venkatasubramanian V, Mathew R, Mohindra R. Persistence of SARS-COV-2 in body fluids: a bystander or whistle blower. Iran J Microbiol 2020;12:370–5.